Disclosed Amino Acid Sequence Derived From Bacterium (e.g., Mycoplasma, Anaplasma, Etc.) Patents (Class 424/190.1)
-
Publication number: 20130230550Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant. In some embodiments, the methods and compositions involve SdrD, ClfA, and/or FnbpB polypeptides.Type: ApplicationFiled: September 9, 2011Publication date: September 5, 2013Applicant: The University of ChicagoInventors: Olaf Schneewind, Alice G. Cheng, Dominique M. Missiakas, Hwan Keun Kim, Hye-Young Kim
-
Patent number: 8524251Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: GrantFiled: January 26, 2012Date of Patent: September 3, 2013Assignees: J. Craig Venter Institute, Inc., Novartis AGInventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
-
Patent number: 8524246Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis, of secreted immunodominant antigens.Type: GrantFiled: December 19, 2012Date of Patent: September 3, 2013Assignee: Actogenix N.V.Inventors: Pieter Rottiers, Veerle Snoeck
-
Publication number: 20130216568Abstract: The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS).Type: ApplicationFiled: February 28, 2011Publication date: August 22, 2013Inventors: Domenico Maione, Cira Daniela Rinaudo
-
Publication number: 20130209501Abstract: The present invention relates to immunogenic compositions, comprising polypeptides isolated from Staphylococcus epidermidis. The invention also relates to polynucleotides encoding Staphylococcus epidermidis polypeptides and their use in immunogenic compositions. In addition, the invention relates to methods of inducing an immune response in mammals against Staphylococcus epidermidis and Staphylococcus aureus using immunogenic compositions of the Staphylococcus epidermidis polypeptides and polynucleotides. The invention also relates to methods for detecting Staphylococcus epidermidis in a biological sample.Type: ApplicationFiled: April 19, 2013Publication date: August 15, 2013Applicant: Wyeth LLCInventor: Wyeth LLC
-
Publication number: 20130209500Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.Type: ApplicationFiled: March 8, 2013Publication date: August 15, 2013Applicant: Infectious Disease Research InstituteInventor: Infectious Disease Research Institute
-
Publication number: 20130202609Abstract: The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The mutants are useful, inter alia, in vaccine compositions to induce protection against S. pyogenes. The antibodies are useful, e.g., as therapeutics for treating S. pyogenes infections.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Inventors: Immaculada Margarit Y Ros, Guido Grandi, Chiara Zingaretti
-
Patent number: 8501190Abstract: There is provided a vaccine for controlling Clostridium perfringens in animals, and particularly necrotic enteritis in poultry. The vaccine may comprise a C. perfringens antigenic polypeptide or variant thereof, a nucleic acid encoding the C. perfringens antigenic polypeptide or variant thereof, or a recombinant cell producing the C. perfringens antigenic polypeptide or variant thereof.Type: GrantFiled: May 30, 2008Date of Patent: August 6, 2013Assignee: The University of GuelphInventors: John Prescott, Raveendra Kulkarni, Valeria Parreira, Shayan Sharif
-
Patent number: 8501197Abstract: This invention provides a method for stimulating in an individual an immune response against M. catarrhalis. The method comprises administering to an individual a composition comprising M. catarrhalis OppA protein in an amount effective to stimulate an immune response against M. catarrhalis in the individual.Type: GrantFiled: April 29, 2011Date of Patent: August 6, 2013Assignee: The Research Foundation for The State of New YorkInventors: Timothy F. Murphy, Min Yang
-
Publication number: 20130195907Abstract: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: June 10, 2011Publication date: August 1, 2013Applicant: Norvartis AGInventors: Renata Maria Grifantini, Erika Bartolini, Oretta Finco, Guido Grandi
-
Publication number: 20130189295Abstract: The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence.Type: ApplicationFiled: June 24, 2011Publication date: July 25, 2013Applicant: Novartis AGInventors: Maria Aricò, Brunella Brunelli, Maurizio Comanducci, Mariagrazia Pizza, Silvana Savino, Maria Scarselli
-
Patent number: 8492103Abstract: The present invention provides an isolated Ehrlichia peptide and therapeutic and diagnostic uses therefor.Type: GrantFiled: January 31, 2012Date of Patent: July 23, 2013Assignee: The Board of Regents of the University of Texas SystemInventors: Sunil Thomas, David H. Walker
-
Publication number: 20130183331Abstract: Leptospira outer membrane proteins (OMPs) LP1454, LP1118, LP1939, MCEII, CADF-like1, CADF-like2, CADF-like3, Lp0022, Lp1499, Lp4337, Lp328 or L21 are provided. The OMPS can be used as tools for developing effective vaccines or diagnostic methods for leptospirosis. Expression vectors for the OMP genes are further provided. The antigenic properties of the Leptospira OMPs can be used to create, manufacture or improve vaccines. Vaccines, including but not limited to DNA vaccines, recombinant vaccines, and T-cell epitope vaccines based on the foregoing OMPs are also provided. Methods for producing such vaccines are also provided. Also provided are methods for using Leptospira OMP genes, proteins and antibodies for therapeutic treatment and serological diagnosis techniques.Type: ApplicationFiled: December 28, 2012Publication date: July 18, 2013Applicant: Cornell UniversityInventor: Cornell University
-
Publication number: 20130183330Abstract: A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing E. coli that may produce as an inclusion body a fusion peptide consisting of peptides derived from outer-membrane protein of Avibacterium paragarinarum serotype A and serotype C, step of culturing said E. coli and colleting and purifying inclusion body from culture, and step of preparing a preparation comprising said purified inclusion body, and an avian infectious coryza vaccine comprising as an active ingredient the fusion peptide. A linker sequence may be inserted between the respective peptides comprising the fusion peptide. For the peptide derived from the serotypes A and C, an amino acid sequence region of Region 2 or its vicinity responsible for protection from infection may be used.Type: ApplicationFiled: September 14, 2012Publication date: July 18, 2013Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Ryuichi SAKAMOTO, Susumu Baba, Masashi Sakaguchi, Hiroshi Mizokami
-
Publication number: 20130183350Abstract: This disclosure relates to immunogenic compositions comprising an isolated immunogenic S. pneumoniae PcpA polypeptide and at least one additional antigen (such as for example, an isolated immunogenic S. pneumoniae polypeptide selected from the group consisting of the polyhistidine triad family of proteins (e.g. PhtD) and methods of using these compositions for preventing and treating diseases caused by S. pneumoniae.Type: ApplicationFiled: December 20, 2010Publication date: July 18, 2013Inventors: Kevin Harper, Belma Ljutic, Scott Gallichan, Martina Ochs-Onolemhemhen, Garry Morefield, Fernando Ausar, Marie-Danielle Salha
-
Publication number: 20130183377Abstract: The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity.Type: ApplicationFiled: September 14, 2011Publication date: July 18, 2013Applicants: UNIVERSITY OF MELBOURNE, COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Javed Naim Agrewala, Uthaman Gowthaman, David Jackson, Weiguang Zeng
-
Patent number: 8486414Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infection.Type: GrantFiled: April 4, 2008Date of Patent: July 16, 2013Assignee: Infectious Disease Research InstituteInventors: Steven G. Reed, Rhea N. Coler, Gregory C. Ireton, Sylvie Bertholet
-
Patent number: 8486411Abstract: The present invention provides a method of classifying an epitope displayed by a polypeptide; a method of determining the presence of an epitope on a polypeptide encoded by a test nucleotide sequence; and a method of generating a nucleotide sequence encoding a polypeptide that exhibits a selected epitope. The present invention provides antigenic polypeptides that display selected epitope(s); chimeric macromolecules comprising such polypeptides; and compositions comprising the antigenic polypeptides or chimeric macromolecules. The present invention further provides methods of inducing an immune response to a Chlamydia. The present invention further provides arrays of nucleic acids, arrays of polypeptides, and arrays of antibodies, which arrays are useful in identification and/or classification of a Chlamydia.Type: GrantFiled: August 29, 2006Date of Patent: July 16, 2013Assignee: Children's Hospital & Research Center at OaklandInventor: Deborah Dean
-
Patent number: 8481692Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: GrantFiled: April 20, 2012Date of Patent: July 9, 2013Assignee: Wyeth LLCInventors: Maninder K. Sidhu, Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
-
Patent number: 8481045Abstract: Bacterial immunity proteins are utilized to increase immune response to an antigen of interest.Type: GrantFiled: January 14, 2010Date of Patent: July 9, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: James Robert Swartz, Junhao Yang, Alexei M. Voloshin, Ronald Levy, Gregg Kanter, Shoshana Levy
-
Publication number: 20130171184Abstract: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention comprise the Hsf (also called Msf) and Opc neisserial antigens. These antigens have been found to be the two mechanisms by which Neisseria meningitidis binds host vitronectin (in order to promote adhesion and/or to evade host complement mediated killing). Vaccines comprising both antigens can thus advantageously result in an immune response which is better able to kill neisserial strains and otherwise prevent vitronectin-related neisserial complement mediated killing resistance and/or neisserial adhesion events required for pathogenesis.Type: ApplicationFiled: September 9, 2011Publication date: July 4, 2013Applicant: MACK TRUCKS INC.Inventor: Mumtaz Virji
-
Publication number: 20130171238Abstract: The invention relates to immunogenic compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. The composition may comprise at least two components, one component of which comprises Chlamydia trachomatis antigens for eliciting a Chlamydia trachomatis specific TH1 immune response and another component of which comprises antigens for eliciting a Chlamydia trachomatis specific TH2 immune response. The invention further relates to an immunogenic composition comprising a Chlamydia trachomatis Type III secretion system (TTSS) regulatory protein and a Chlamydia trachomatis Type III secretion system (TTSS) secreted protein or a fragment thereof. The invention further relates to the use of combinations of adjuvants for use with antigens associated with a sexually transmissible disease, such as Chlamydia trachomatis antigens. Preferred adjuvant combinations include mineral salts, such as aluminium salts and oligonucleotides comprising a CpG motif.Type: ApplicationFiled: January 4, 2013Publication date: July 4, 2013Applicant: NOVARTIS AGInventor: NOVARTIS AG
-
Publication number: 20130171183Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.Type: ApplicationFiled: July 1, 2011Publication date: July 4, 2013Applicant: UNIVERSITY OF CHICAGOInventor: Olaf Schneewind
-
Patent number: 8475803Abstract: The invention relates to the identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis and the discrimination between infected animals and animals previously exposed to vaccines.Type: GrantFiled: May 2, 2006Date of Patent: July 2, 2013Assignee: Fusion Antibodies LimitedInventors: Shane A. Olwill, Richard J. Buick, Hangfai Kwok, James A. Johnston
-
Publication number: 20130164317Abstract: Provided herein is a biologically pure culture of Paenibacillus thiaminolyticus, identified as OSY-SE, as well as an antimicrobial agent isolated and/or purified from the culture having any one of SEQ ID NOs:1-3 and 64-66. The disclosure also provides compositions and articles of manufacture comprising an antimicrobial agent and/or the bacterial cell of Paenibacillus thiaminolyticus, identified as OSY-SE. Further provided are methods of use, including methods of affecting microbial activity, methods of inhibiting growth and/or proliferation of a microbe, methods of treating a condition or disease associated with the presence of a microbe, and methods of treating a microbial infection in a subject comprising contacting a microbial cell with at least one active agent of SEQ ID NOs:1-3 and 64-66 and/or the bacterial cell Paenibacillus thiaminolyticus, identified as OSY-SE. The disclosure also provides the biosynthetic machinery (e.g.Type: ApplicationFiled: December 5, 2012Publication date: June 27, 2013Inventors: Ahmed E. Yousef, Yaoqi Guo, En Huang, Chunhua Yuan, Liwen Zhang
-
Publication number: 20130164298Abstract: The present invention provides an antigenic composition, the composition comprising at least one recombinant protein. The recombinant protein comprises at least one epitope. The epitope is reactive with an antibody which is reactive with a polypeptide having the sequence set out in SEQ. ID. NO. 3 or SEQ. ID. NO. 5. The invention also provides methods and compositions for the production of the recombinant protein. Also provided are methods for the diagnosis, treatment and prevention of P. gingivalis infection.Type: ApplicationFiled: August 3, 2012Publication date: June 27, 2013Inventors: Eric Charles Reynolds, Nada Slakeski, Chao Guang Chen, Ian George Barr
-
Patent number: 8470340Abstract: Polypeptides that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.Type: GrantFiled: September 2, 2009Date of Patent: June 25, 2013Assignees: Children's Hospital & Research Center Oakland, Novartis Vaccines and Diagnostics, SRL, Universita degli Studi del MoliseInventors: Peter Beernink, Franco Felici, Dan M. Granoff
-
Patent number: 8470339Abstract: The present invention discloses new antigens of Mycobacterium avium subsp. paratuberculosis, antigenic compositions comprising at least two of said antigens, as well as epitopes, antibodies or hypervariable fragments thereof and nucleotide sequences coding for them. The present invention also concerns their use in diagnosis and/or vaccination against Mycobacterium avium subsp. paratuberculosis, in mammals, and in particular in cattle, but also in sheep and caprines. The invention also concerns their potential application in diagnosis and/or vaccination against Crohn's disease in human.Type: GrantFiled: November 6, 2007Date of Patent: June 25, 2013Assignees: Universite de Mons, Cerva-Coda, Institut Scientifique de Sante PubliqueInventors: Baptiste Leroy, Ruddy Wattiez, Christiane A. J. Huygen, Virginie Roupie, Marc Govaert, Isabelle Georis
-
Patent number: 8470974Abstract: The present invention intends to provide an assay system using split luciferase that has a remarkably high detection sensitivity. In an embodiment, binding of mutually binding first and second proteins is detected by preparing a first fusion protein comprising the first protein fused with a peptide having the amino acid sequence of amino acid SEQ ID NO: 1 and a second fusion protein comprising the second protein fused with a peptide having an amino acid sequence selected from the group consisting of amino acid SEQ ID NOS: 2 to 6, and allowing the first fusion protein to bind with the second fusion protein to form a complex, and detecting luminescence emitted from the complex.Type: GrantFiled: May 28, 2010Date of Patent: June 25, 2013Assignees: The University of Tokyo, ProbeX Inc., Tokyo Boseki Kabushiki KaishaInventors: Takeaki Ozawa, Naomi Misawa, Kenji Miura, Tasuku Okamoto, Shigeaki Nishii, Kenji Masuda
-
Publication number: 20130156802Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.Type: ApplicationFiled: December 16, 2011Publication date: June 20, 2013Inventor: Juliette Tinker
-
Publication number: 20130156805Abstract: The present invention regards polypeptides capable of eliciting an immunological response that is protective against Chlamydia trachomatis. The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2. Furthermore, production of these polypeptides and pharmaceutical compositions comprising them are also provided.Type: ApplicationFiled: May 27, 2011Publication date: June 20, 2013Applicant: SPIXIA BIOTECHNOLOGY ABInventors: Sören Andersson, Åke Strid
-
Publication number: 20130156775Abstract: Proteins encoded by Chlamydia trachomatis which are immunogenic in humans as a consequence of infection have been identified using Western blots of two-dimensional electrophoretic maps. Several known immunogens were identified, as were proteins not previously known to be immunogens, and proteins not previously reported as expressed gene products.Type: ApplicationFiled: January 5, 2012Publication date: June 20, 2013Inventor: Giulio Ratti
-
Publication number: 20130156804Abstract: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila.Type: ApplicationFiled: November 20, 2012Publication date: June 20, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: The Regents Of The University Of California
-
Publication number: 20130156803Abstract: Disclosed are compositions and methods related to vaccination for AOM and children prone to AOM.Type: ApplicationFiled: June 4, 2012Publication date: June 20, 2013Inventors: MICHAEL PICHICHERO, M. NADEEM KHAN, RAVINDER KAUR, SHARAD SHARMA, JANET CASEY, LEA MICHEL
-
Patent number: 8465751Abstract: The invention provides protective antigens which are useful in vaccine compositions to induce protection against gram positive bacteria, particularly against S. agalactiae, S. pyogenes, S. pneumoniae, S. aureus, S. suis, and S. equi.Type: GrantFiled: January 12, 2010Date of Patent: June 18, 2013Assignee: Novartis AGInventors: Andrea Guido Oreste Manetti, Immaculada Margarit Y Ros, Guido Grandi
-
Publication number: 20130149326Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.Type: ApplicationFiled: February 14, 2013Publication date: June 13, 2013Applicant: NOVARTIS AGInventor: Novartis AG
-
Publication number: 20130149325Abstract: The present invention relates to isolated Porphyromonas gingivalis polypeptides and nucleotides. The polypeptides include an amino acid sequence selected from the group consisting of: SEQ. ID. NO. 110; SEQ. ID. NO. 111; SEQ. ID. NO. 112; SEQ. ID. NO. 113; SEQ ID NO: 120; SEQ. ID. NO. 123; SEQ. ID. NO. 124; SEQ. ID. NO. 125; SEQ. ID. NO. 130; SEQ. ID. NO. 131; SEQ. ID. NO. 132; SEQ. ID. NO. 133; SEQ. ID. NO. 135; SEQ. ID. NO. 136; SEQ. ID. NO. 137; SEQ. ID. NO. 138; SEQ. ID. NO. 143; SEQ. ID. NO. 144; SEQ. ID. NO. 145; SEQ. ID. NO. 146; SEQ. ID. NO. 147; SEQ. ID. NO. 148; and amino acid sequences at least 95% identical thereto.Type: ApplicationFiled: February 21, 2012Publication date: June 13, 2013Inventors: BRUCE C. ROSS, IAN G. BARR, MICHELLE A. PATTERSON, CATHERINE T. AGIUS, LINDA J. ROTHEL, MAI B. MARGETTS, DIANNA M. HOCKING, ELIZABETH A. WEBB
-
Publication number: 20130149324Abstract: Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis.Type: ApplicationFiled: February 9, 2012Publication date: June 13, 2013Applicant: Statens Serum InstitutInventors: PETER ANDERSEN, Ida Rosenkrands, Anette Stryhn
-
Publication number: 20130149327Abstract: The present invention provides antigens and vaccines useful in prevention of infection by Yersinia pestis. The present invention provides pharmaceutical compositions of such antigens and/or vaccines. The present invention provides methods for the production of Y. pestis protein antigens in plants, as well as methods for their use in the treatment and/or prevention of Y. pestis infection.Type: ApplicationFiled: February 25, 2013Publication date: June 13, 2013Applicant: FRAUNHOFER USA, INCInventor: FRAUNHOFER USA, INC
-
Patent number: 8461323Abstract: The present invention relates, in general, to polypeptides having antigenic epitopes from granulocytic ehrlichia (GE) proteins and methods of use thereof.Type: GrantFiled: January 9, 2012Date of Patent: June 11, 2013Assignee: Antigenics, Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Publication number: 20130142803Abstract: The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type IV pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and polypeptides encoded by the polynucleotides as well as polynucleotides and polypeptides encoded by the polynucleotides involved in the assembly/disassembly of the structure. The invention also relates to uses of these polynucleotides and/or polypeptides including methods for eliciting an immune response to H. influenzae and methods of treating and preventing H. influenzae related pathological conditions.Type: ApplicationFiled: February 13, 2013Publication date: June 6, 2013Applicant: Nationwide Children's Hospital, Inc.Inventor: Nationwide Children's Hospital, Inc.
-
Publication number: 20130142800Abstract: There is provided an antigenic composition comprising (a) a first mycobacterial antigenic polypeptide or a first mycobacterial polynucleotide; and (b) a second mycobacterial antigenic polypeptide or a second mycobacterial polynucleotide; wherein: (i) said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1 or 7, or a fragment thereof having at least 7 consecutive amino acids thereof; (ii) said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide; (iii) said second mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 5, or a fragment thereof having at least 7 consecutive amino acids thereof; and (iv) said second mycobacterial polynucleotide comprises a polynucleotide sequence encoding said second mycobacterial polypeptidType: ApplicationFiled: May 23, 2011Publication date: June 6, 2013Applicant: HEALTH PROTECTION AGENCYInventors: Miles Carroll, Yper Hall, Ann Williams
-
Patent number: 8455210Abstract: The present invention relates to a method for the selective identification of Chlamydia trachomatis infections wherein the antigens CT017, CT098, CT318-L1 P, CT431-TARP, CT603-TSAP, and CT664 are used for the specific identification of Chlamydia trachomatis antibodies in samples from mammals. The method according to the invention facilitates the selective identification method of identification of Chlamydia trachomatis infections, in which no false positive results are generated by other Chlamydia species such as, for example, Chlamydia pneumoniae. The invention further relates to a biochip which has the aforementioned Chlamydia trachomatis-specific antigens for the identification of antibodies. The biochip with antigens according to the invention is suitable for multiparameter identification methods in particular.Type: GrantFiled: March 7, 2008Date of Patent: June 4, 2013Assignee: Mikrogen GmbHInventors: Ulrike Simnacher, Vera Forsbach-Birk, Andreas Essig, Klaus-Ingmar Pfrepper
-
Publication number: 20130136760Abstract: The present invention relates to antigens, more particularly antigenS of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.Type: ApplicationFiled: October 24, 2012Publication date: May 30, 2013Applicant: ID BIOMEDICAL CORPORATION OF QUEBECInventor: ID Biomedical Corporation of Quebec
-
Publication number: 20130136761Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pneumoniae, methods for isolating such antigens and specific uses thereof.Type: ApplicationFiled: January 31, 2013Publication date: May 30, 2013Applicant: Intercell AGInventor: Intercell AG
-
Publication number: 20130136762Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: ApplicationFiled: February 1, 2013Publication date: May 30, 2013Applicant: The University of QueenslandInventor: The University of Queensland
-
Patent number: 8449892Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, and methods for isolating such antigens and specific uses thereof.Type: GrantFiled: March 7, 2011Date of Patent: May 28, 2013Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky
-
Patent number: 8449891Abstract: The present invention provides an optimized recombinant flagellin protein and preparation and use thereof. The protein is with a deletion in the hypervariable region, said hypervariable region is the region from 180 to 400 amino acid of the flagellin protein, and the proteins include FliC?190-278, FliC?220-320 or FliC?180-400. The method of preparing said protein, comprising introducing a deletion into the hypervariable region of the flagellin protein. First constructed the flagellin protein recombinant plasmid, and then used it as template to construct the flagellin deletion cloning, and expressed and purified. The present invention also provides the use of the recombinant flagellin protein as adjuvant. The recombinant flagellin protein in present invention decreases the potential risks it may have, and decreases its antigenicity and immunogenicity and the inflammatory response induced by it, through deleting its main areas of immunogenicity and antigen activity.Type: GrantFiled: August 9, 2010Date of Patent: May 28, 2013Assignee: Wuhan Institute of Virology, Chinese Academy of SciencesInventors: Huimin Yan, Fang Liu, Jingyi Yang
-
Publication number: 20130129737Abstract: This invention provides an isolated nucleic acid encoding a polypeptide comprising amino acid sequences of a streptococcal matrix adhesion E (EmaE) polypeptide. Antibodies to the EmaE polypeptide and immunogenic fragments thereof are also provided. This invention provides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptide, antibodies thereto, and nucleic acids.Type: ApplicationFiled: February 18, 2011Publication date: May 23, 2013Applicants: University of Utah Research Foundation, St. Jude Children's Research HospitalInventors: Elisabeth Adderson, John Bohnsack
-
Publication number: 20130129763Abstract: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.Type: ApplicationFiled: November 1, 2012Publication date: May 23, 2013Inventors: ARNE FORSGREN, KRISTIAN RIESBECK